The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes

被引:83
|
作者
Nichols, GA [1 ]
Brown, JB [1 ]
机构
[1] Ctr Hlth Res, Portland, OR 97227 USA
关键词
D O I
10.2337/diacare.25.3.482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-We examined whether cardiovascular disease (CVD) affects medical care costs differently in subjects with and without diabetes and explored the impact of CVD on costs across the dimensions of age and diabetes duration. Research Design and Methods-We compared the prevalence of CVD and medical care costs for subjects with and without CVD in all 16,180 full-year health maintenance organization members in 1999 who had been diagnosed with type 2 diabetes and in control members matched by year of birth and sex. We ascertained diagnoses from the Kaiser Permanente Northwest Region's electronic ambulatory medical record and from hospital discharge datafiles. Utilization from these and other data systems were multiplied by unit costs. Results-CVD was 76% more prevalent in subjects with diabetes, but the risk ratios of more severe forms of CVD were even greater. Risk ratios for CVD were greatest in younger subjects. Cost profiles for subjects with both CVD and diabetes differed markedly from those with diabetes but without CVD. In the latter group, costs grew steadily with age, whereas in the former group, costs peaked in the 55- to 64-year age group before declining with age. Conclusions-The types of CVD present in diabetic patients are more likely to be more severe and therefore more costly than in similar subjects without diabetes. CVD also disproportionately affects younger diabetic subjects. Finally, when CVD is present in diabetes, more costs occur earlier in life as well as earlier in the course of diabetes.
引用
收藏
页码:482 / 486
页数:5
相关论文
共 50 条
  • [1] Impact of cardiovascular disease on medical care costs in persons with and without type 2 diabetes
    Nichols, GA
    Brown, JB
    DIABETOLOGIA, 2001, 44 : A252 - A252
  • [2] Impact of cardiovascular disease on health care costs in persons with and without type 2 diabetes
    Nichols, GA
    Brown, JB
    DIABETES, 2001, 50 : A1 - A1
  • [3] Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
    Nichols, Gregory A.
    Ustyugova, Anastasia V.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    DIABETES, 2019, 68
  • [4] The impact of age at diagnosis on cost of medical care in subjects with Type 2 diabetes
    Pedula, KL
    Brown, JB
    Hillier, TA
    DIABETOLOGIA, 2002, 45 : A41 - A41
  • [5] Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease
    Mehta, Sandhya
    Ghosh, Sabyasachi
    Sander, Stephen
    Kuti, Effie
    Mountford, William K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (03): : 280 - +
  • [6] Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)
    Yokoyama, H.
    Araki, S.
    Kawai, K.
    Hirao, K.
    Oishi, M.
    Sugimoto, K.
    Sone, H.
    Maegawa, H.
    Kashiwagi, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 109 (03) : 485 - 492
  • [7] Medical costs of managed care in patients with type 2 diabetes mellitus
    Bhattacharyya, SK
    Else, BA
    CLINICAL THERAPEUTICS, 1999, 21 (12) : 2131 - 2142
  • [8] Growth in medical care costs after diagnosis of type 2 diabetes
    Glauber, HS
    Brown, JB
    Nichols, GA
    Bakst, AW
    DIABETOLOGIA, 1998, 41 : A253 - A253
  • [9] Costs of cardiovascular and renal complications in type 2 diabetes by stage of disease
    Brown, JB
    Pedula, KL
    Glauber, HS
    Bakst, AW
    DIABETOLOGIA, 1998, 41 : A254 - A254
  • [10] Total costs of care in patients with type 2 diabetes and cardiovascular disease: a comparative cohort study (OFFSET)
    Evans, M.
    Chandramouli, A. Shankar
    Faurby, M.
    Matthiessen, K. Sommer
    BredahlMogensen, P.
    Verma, S.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 140 - 141